ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2285

Correlation Of Individual Health Assessment Questionnaire (HAQ) Questions With Outcome Measures In Rheumatoid Arthritis: Implications For Instrument Reduction

J. Carter Thorne1, Majed M. Khraishi2, Boulos Haraoui3,4, Jude F. Rodrigues5, Algis Jovaisas6, Denis Choquette3, Sanjay Dixit7, Dalton E. Sholter8, Philip Baer9, Maqbool K. Sheriff10, Emmanouil Rampakakis11,12, John S. Sampalis11,12, Francois Nantel13, Allen J. Lehman14, May Shawi15 and Susan M. Otawa14, 1Southlake Regional Health Centre, Newmarket, ON, Canada, 2Nexus Clinical Research, St John's, NF, Canada, 3Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 4Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 5Rheumatology, Windsor, ON, Canada, 6Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 7McMaster University, Hamilton, ON, Canada, 8Rheumatology Associates, Edmonton, AB, Canada, 9Private Practice, Scarborough, ON, Canada, 10Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Jewish General Hospital, McGill University, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: functional status, patient outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Despite the importance of the Health Assessment Questionnaire (HAQ) in assessing patient-reported functional status, it was originally developed primarily for research studies. As a result, HAQ has been critiqued for being time-consuming, not easily scored, and, thus, not contributing to decisions made in routine clinical care as well as for assessing general health and not specifically the clinical status of Rheumatoid Arthritis (RA).

The aim of this analysis is to describe the correlation of the individual HAQ questions with other outcome measures used in RA as well as to examine whether the instrument could be reduced to better reflect routine clinical practice.

Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with infliximab or golimumab as first biologics or after having been treated with a biologic for less than 6 months. In this analysis, data from RA patients who were treated with infliximab between January 2002 and June 2011 were used. Parameter correlation was described with the Pearson’s correlation coefficient and the impact of each question on the use of aids/devices/help was assessed with logistic regression. Factor analysis was used to assess variability in HAQ score due to each of the individual questions.

Results: 877 RA patients who had 4,180 complete HAQ assessments were included in the analysis. Higher pain score, patient assessment of global disease activity (PtGA), 28-tender joint count (TJC-28) and, to a lesser extent, 28-swollen joint count (SJC-28) were associated with increased functional impairment. Correlation analysis showed that individual HAQ questions correlated at different extents with each outcome measure (SJC-28) (Table 1). Notably, Q5B showed the lowest correlation with patient outcome measures while the two questions related to “Rising” (Q2A, Q2B) showed the highest overall correlation.

Logistic regression showed that all individual questions were significantly associated with the use of aids/devices/help within their corresponding category with the exception of Q3B and Q8B. In factor analysis, “Dressing and Grooming” was found to account for 66.5% of the matrix variance (Q1A: 60.5%; Q1B: 6.0%) suggesting that the ability to dress/groom alone may be the main driver of the HAQ score.

Conclusion: Results of this analysis show that variability exists in the correlation of individual HAQ questions with patient-reported and clinical outcome measures. Pain and joint tenderness are significantly associated with the individual functions of the HAQ while the number of swollen joints appears to be of minor importance. Furthermore, the ability to dress/groom alone was the main driver of the variability in HAQ which may have implications from an occupational health perspective and in the design of self-report instruments assessing the (dis)ability to perform daily activities.

Table 1: Correlation between individual HAQ Questions and Outcome Measures

HAQ Question

Pain

PtGA

TJC-28

SJC-28

Q1A: Dress alone

0.58

0.58

0.40

0.35

Q1B: Shampoo hair

0.48

0.48

0.36

0.29

Q2A: Stand up from chair

0.61

0.61

0.42

0.36

Q2B: Get in/out of bed

0.62

0.61

0.43

0.36

Q3A: Cut meat

0.50

0.50

0.37

0.31

Q3B: Lift a full cup/glass

0.49

0.48

0.35

0.33

Q3C: Open milk carton

0.52

0.53

0.40

0.35

Q4A: Walk outdoor on flat ground

0.56

0.55

0.36

0.31

Q4B: Climb up five steps

0.58

0.58

0.39

0.31

Q5A: Wash/dry body

0.55

0.54

0.40

0.33

Q5B: Take a tub bath

0.42

0.41

0.29

0.26

Q5C: Get on/off toilet

0.55

0.54

0.39

0.34

Q6A: Reach and get down object

0.53

0.52

0.38

0.32

Q6B: Pick clothing from floor

0.57

0.56

0.40

0.30

Q7A: Open car door

0.48

0.49

0.41

0.34

Q7B: Open jar

0.52

0.53

0.40

0.36

Q7C: Turn faucet on/off

0.47

0.48

0.40

0.35

Q8A: Run errands/shop

0.55

0.54

0.40

0.30

Q8B: Get in/out of car

0.60

0.59

0.43

0.36

Q8C: Do chores

0.52

0.51

0.37

0.29

* Weak: r < 0.30; Moderate: r = 0.30-0.39; Strong: 0.40-0.69; Very Strong: ≥0.70

.

 


Disclosure:

J. C. Thorne,
None;

M. M. Khraishi,

Hoffman-La Roche Canada, Amgen and Pfizer Canada, and Abbott Canada.,

2;

B. Haraoui,
None;

J. F. Rodrigues,
None;

A. Jovaisas,

Janssen Pharmaceutica Product, L.P ,

5;

D. Choquette,
None;

S. Dixit,
None;

D. E. Sholter,
None;

P. Baer,

Janssen Pharmaceutica Product, L.P.,

5;

M. K. Sheriff,
None;

E. Rampakakis,
None;

J. S. Sampalis,
None;

F. Nantel,
None;

A. J. Lehman,

Janssen Canada,

3;

M. Shawi,

Janssen Canada,

3;

S. M. Otawa,

Janssen Canada,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-individual-health-assessment-questionnaire-haq-questions-with-outcome-measures-in-rheumatoid-arthritis-implications-for-instrument-reduction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology